Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery

NCT06678399 is registered in ClinicalTrials.gov with Kelifarma as lead sponsor.

NCT NCT06678399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06678399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery
Lead sponsor
Kelifarma
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
April 1, 2025
Completion date
January 1, 2027
Enrollment
91 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

preemptive therapy of patients at risk for acute kidney injury following cardiac surgery